MedPath

A comparative study on the effectiveness of Electroconvulsive therapy and ketamine in person suffering from depressive disorder not responding to medications

Not Applicable
Completed
Conditions
Health Condition 1: F322- Major depressive disorder, singleepisode, severe without psychotic featuresHealth Condition 2: null- treatment resistant depression
Registration Number
CTRI/2020/08/027340
Lead Sponsor
Ahana hospitals LLP
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
96
Inclusion Criteria

1.Age range 18-60 years

2.Male and Female

3.Written informed consent.

4.Presence of Major Depressive Disorder as per DSM V guidelines

5.Refractory to at least two anti-depressant medications

Exclusion Criteria

1. Co-morbid psychiatric diagnoses such

as psychosis, bipolar disorder, substance dependence (including nicotine dependence)

2. Mental retardation, neurological disorders and severe medical illness

3. pregnancy or breast feeding

4.Diagnosis of major depressive disorder with psychotic features during the current depressive episode

5.allergy to ketamine

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Patient reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 2-3 weeks ] <br/ ><br>Response is defined as at least a 50% improvement in Baseline QIDS-SR-16 score at End of Treatment Visit. The End of Treatment Visit will occur 3-5 weeks after the Baseline Visit. <br/ ><br>Timepoint: baseline and 2-3 weeks <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
clinician reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 3-5 weeks ] <br/ ><br>Number of patients with an improvement in their Baseline MADRS score at the End of Treatment Visit. The End of Treatment Visit will occur 2-3 weeks after the Baseline Visit. <br/ ><br>Timepoint: baseline and 2-3 weeks
© Copyright 2025. All Rights Reserved by MedPath